Trial intelligence / Profile preview

SPIDER: Specifying the Anti‑inflammatory Effects of Ziltivekimab

2024-515893-29-01Phase 3Authorised

Sponsor: Amsterdam University Medical Center
Start: Nov 2024
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 3, randomised, double-blind trial in coronary arteriosclerosis comparing Ziltivekimab with Placebo (2 arms). Primary endpoint: Primary: Change in coronary TBRmax and monocyte activation markers. Planned start Nov 2024; status: authorised.

Drugs

ziltivekimab

Conditions

coronary arteriosclerosis

Beyond the preview

Go deeper on 2024-515893-29-01.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-515893-29-01.